Prices delayed by at least 15 minutes | Print
Faron Pharmaceuticals Oy (FARN)
ORD NPV (DI)This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Company profile
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.
Address
Joukahaisenkatu 6, Intelligate
Turku
FIN
FI-20520
Telephone
+358 24695151
Forecast key dates
| Name | Key Date |
|---|---|
| Faron Pharmaceuticals Oy Annual General Meeting for 2025 | 2026-03-20T10:00:00 |
| Faron Pharmaceuticals Oy Fourth Quarter Earnings Conference Call for 2025 | 2026-02-27T09:00:00 |
| Faron Pharmaceuticals Oy Fourth Quarter Earnings Results for 2025 | 2026-02-27T00:00:00 |
| Faron Pharmaceuticals Oy Annual Report for 2025 | 2026-02-27T00:00:00 |
| Faron Pharmaceuticals Oy Second Quarter Earnings Result for 2025 | 2025-08-27T00:00:00 |
| Faron Pharmaceuticals Oy Second Quarter Earnings Conference Call for 2025 | 2025-08-27T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Faron Pharmaceuticals Oy Annual General Meeting for 2024 | 2025-03-21T10:00:00 |
| Faron Pharmaceuticals Oy Fourth Quarter Earnings Conference Call for 2024 | 2025-02-27T09:00:00 |
| Faron Pharmaceuticals Oy Fourth Quarter Earnings Result for 2024 | 2025-02-27T00:00:00 |
| Faron Pharmaceuticals Oy Annual Report for 2024 | 2025-02-27T00:00:00 |
| Faron announces Capital Markets Day | 2024-10-22T08:00:00 |
| Faron Pharmaceuticals Oy Second Quarter Earnings Conference Call for 2024 | 2024-08-28T13:00:00 |
| Faron Pharmaceuticals Oy Second Quarter Earnings Results for 2024 | 2024-08-27T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.